Ivabradin Stada

Ivabradine, the active ingredient in Ivabradin Stada, is an If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is indicated for chronic stable angina and certain forms of heart failure in adult patients. GNH USA supplies Ivabradin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Ivabradin Stada acts on the cardiac If current, making it useful in several heart‑related conditions. - Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance by lowering heart rate. - Heart failure with reduced ejection fraction: decreases hospitalization risk and enhances symptom control through heart‑rate reduction. - Ischemic heart disease: helps control myocardial oxygen demand by maintaining a lower heart rate. - Tachycardia associated with angina: provides rate control when beta‑blockers are insufficient or contraindicated.

Ivabradin Stada may cause a range of adverse reactions, which are categorized by frequency. Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena, usually mild and reversible. - Bradycardia: heart‑rate reduction below 50 beats/min in some patients. - Headache: mild to moderate intensity, often transient. - Dizziness: sensation of light‑headedness, especially on standing. Serious or Rare Side Effects: - Symptomatic severe bradycardia: may cause fatigue, hypotension, or syncope. - Atrial fibrillation: irregular rapid heart rhythm requiring medical evaluation. - Persistent visual impairment: rare cases of lasting visual field changes.

Before prescribing Ivabradin Stada, clinicians should consider several safety precautions to minimize risk. - Cardiovascular assessment: evaluate baseline heart rate and conduction system. - Conduction disorders: avoid in patients with sick sinus syndrome or second‑degree AV block. - Severe hepatic impairment: use with caution or avoid as metabolism is reduced. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Drug interactions: review concomitant medications that affect CYP3A4 or heart rate. - Store below 25°C: keep in the original pack, protect from moisture.

Ivabradin Stada can interact with other medicines, influencing its plasma levels or additive heart‑rate effects. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase ivabradine exposure. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem): may cause excessive heart‑rate reduction. - Concomitant use with other If channel blockers: risk of profound bradycardia. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may raise levels, dose adjustment may be needed. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Nitrates or other anti‑anginal drugs: monitor for additive effects on heart rate and blood pressure.